Tolerance of bradykinin-releasing drugs ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.
Author(s) :
Escure, Guillaume [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Nudel, Morgane [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Farhat, Meryem-Maud [Auteur]
Service de médecine interne [Lille]
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Gautier, Sophie [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Sanges, Sébastien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Nudel, Morgane [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Farhat, Meryem-Maud [Auteur]
Service de médecine interne [Lille]
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Gautier, Sophie [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Sanges, Sébastien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Journal title :
European Journal of Dermatology
Abbreviated title :
Eur J Dermatol
Volume number :
32
Pages :
49-55
Publication date :
2022-05-08
ISSN :
1952-4013
English keyword(s) :
ACE inhibitor
angiotensin receptor blocker
bradykinin-mediated angioedema
C1-inhibitor deficiency
acquired angioedema
angiotensin receptor blocker
bradykinin-mediated angioedema
C1-inhibitor deficiency
acquired angioedema
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Bradykinin-mediated angioedema (AE) manifests as recurrent oedema of the mucosa, skin and abdominal wall, usually lasting 48 to 96 hours. It can be caused by bradykinin-releasing drugs (such as angiotensin converting enzyme ...
Show more >Bradykinin-mediated angioedema (AE) manifests as recurrent oedema of the mucosa, skin and abdominal wall, usually lasting 48 to 96 hours. It can be caused by bradykinin-releasing drugs (such as angiotensin converting enzyme inhibitors [ACEi], angiotensin receptor blockers [ARB] and dipeptidyl peptidase 4 inhibitors [DPP-4i]) or by C1-inhibitor (C1-INH) deficiency, which can be hereditary (HAE) or more rarely acquired (AAE). AAE is classically associated with lymphoid malignancies or monoclonal gammopathy [...]Show less >
Show more >Bradykinin-mediated angioedema (AE) manifests as recurrent oedema of the mucosa, skin and abdominal wall, usually lasting 48 to 96 hours. It can be caused by bradykinin-releasing drugs (such as angiotensin converting enzyme inhibitors [ACEi], angiotensin receptor blockers [ARB] and dipeptidyl peptidase 4 inhibitors [DPP-4i]) or by C1-inhibitor (C1-INH) deficiency, which can be hereditary (HAE) or more rarely acquired (AAE). AAE is classically associated with lymphoid malignancies or monoclonal gammopathy [...]Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Submission date :
2024-01-12T01:33:47Z
2024-03-04T14:59:15Z
2024-03-04T14:59:15Z